SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Drop in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 31,400 shares, a decline of 15.1% from the December 15th total of 37,000 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 25,600 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SOPH. Silverberg Bernstein Capital Management LLC acquired a new stake in SOPHiA GENETICS during the fourth quarter worth about $70,000. Green Alpha Advisors LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth about $79,000. Federated Hermes Inc. grew its holdings in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after acquiring an additional 23,000 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares during the period. 31.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.40.

SOPHiA GENETICS Stock Down 6.3 %

SOPHiA GENETICS stock opened at $2.98 on Friday. The stock has a 50-day moving average of $3.29 and a two-hundred day moving average of $3.69. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a one year low of $2.70 and a one year high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $15.85 million during the quarter, compared to analyst estimates of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. During the same period in the prior year, the company posted ($0.21) earnings per share. Equities research analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.